A randomised controlled study of canagliflozin in improving diabetic kidney disease through a podocyte protection mechanism.
Introduction This study aimed to investigate whether canagliflozin improves diabetic kidney disease (DKD) through a podocyte protective mechanism. Method DKD patients were randomly assigned to the experimental group (87 patients: standard therapy plus cangliflozin 100 mg/day) and the control group (85 patients: stand...